Follow the latest ABBVIE INC. (ABBV) news and market headlines alongside the live ABBV price. Stay informed on what's moving ABBV.
As tech stocks struggle post-election, investors are rotating into defensive sectors like healthcare. The State Street Healthcare Select Sector SPDR ETF (XLV) has gained 23% in 2026, outperforming the S&P 500's 11% return. Healthcare's inelastic demand makes it attractive during market volatility, though investors should consider dollar-cost averaging given the recent run-up.
With the S&P 500 trading at valuations similar to 1999 (driven by AI hype instead of the dot-com boom), the article recommends three dividend stocks positioned to weather potential market corrections: AbbVie for healthcare stability, Enterprise Products Partners for consistent cash flow, and JPMorgan Chase to benefit from rising interest rates.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
AbbVie reported strong Q3 2026 results with immunology revenues rising 16.6% to $9.2 billion, driven by blockbuster drugs Skyrizi (up 22.9%) and Rinvoq (up 24.3%), offsetting Humira's 30.6% decline due to biosimilar competition. The company raised 2026 sales forecasts for both drugs, expecting combined growth exceeding 20%, with new indications in inflammatory bowel disease and dermatology providing additional growth opportunities.
Zacks equity research analysts published analysis on five stocks. NVIDIA faces China restrictions and competition but benefits from AI infrastructure demand. Walmart outperforms its industry with strong omnichannel operations but faces cost pressures. AbbVie offsets Humira's decline with strong growth from newer drugs. Pioneer Bancorp outperforms its industry with solid fundamentals. Aspira significantly underperforms its industry with liquidity constraints and execution risks.
Eli Lilly has established itself as a dominant player in the obesity treatment market, with Mounjaro and Zepbound generating 65% of revenues. The company's April 2026 launch of Foundayo (oral GLP-1) recorded $281 million in sales, offering a more convenient alternative to injectable treatments. Lilly is developing next-generation therapies including retatrutide (triple-acting), eloralintide, and EloraTZP to maintain market leadership. However, competition is intensifying from Novo Nordisk and emerging biotech companies.
The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.
The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.
AbbVie raised its 2026 revenue guidance to $67.8 billion for the third time this year, driven by strong performance from Skyrizi and Rinvoq, which are offsetting Humira's patent-driven decline. The company's neuroscience portfolio, including Vyalev and migraine drugs, is also contributing to growth. However, aesthetics sales remain soft and oncology growth is subdued. AbbVie maintains a Zacks Rank #3 (Hold) rating with solid long-term prospects.
Browse other US stocks in the same sector as ABBVIE INC.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ABBV, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.
